Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503210 | 1.00 | KIF11 (0.59) | KIF11HPGDALDH1A1LMNAMAPT | |
| SCHEMBL29191726 | 0.84 | KIF11 (0.43) | KIF11 | |
| SCHEMBL9065200 | 0.84 | KIF11 (0.43) | KIF11 | |
| Cystine SCHEMBL27941982 | 0.83 | KIF11 (0.65) | KIF11GRIK1GRIK2 | |
| SCHEMBL6223407 | 0.83 | MAOA (0.57) | KIF11 | |
| SCHEMBL342512 | 0.83 | MAOA (0.57) | KIF11 | |
| SCHEMBL1157625 | 0.83 | MAOA (0.57) | KIF11 | |
| SCHEMBL11869200 | 0.82 | KIF11 (0.55) | KIF11ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL11570330 | 0.82 | KIF11 (0.55) | KIF11ALDH1A1LMNAMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL3319856 | 0.81 | MAOA (0.55) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3348567-B1 | NOVEL O-PHOSPHOSERINE EFFLUX PROTEIN VARIANT AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE AND DERIVATIVE THEREOF USING SAME | CJ CHEILJEDANG CORP (KR) | 2020-08-05 | — | — | EP | claimed |
| EP-3181685-B1 | O-PHOSPHOSERINE PRODUCING MICROORGANISM AND METHOD FOR PRODUCING O-PHOSPHOSERINE OR L-CYSTEINE USING SAME | CJ CHEILJEDANG CORP (KR) | 2019-08-14 | — | — | EP | claimed |
| US-20170172957-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9415031-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140221453-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741955-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735451-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120329851-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012166533-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166544-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120302621-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. | 2012-11-29 | — | — | US | disclosed |
| EP-2139461-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | Recepticon Aps (DK) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008113364-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | RECEPTICON APS (DK) | 2008-09-25 | — | — | WO | disclosed |